| T6283 |
Wortmannin
|
19545-26-7
|
98%
|
|
|
Wortmannin (SL-2052) is a PI3K inhibitor (IC50=3 nM) that is covalent and irreversible. Wortmannin is also an inhibitor of PlK1 and PlK3 (IC50=5.8/48 nM) that bl...
|
| T6282 |
GSK461364
|
929095-18-1
|
98%
|
|
|
GSK461364 (GSK461364A)(Ki=2.2 nM) inhibits purified Plk1 .The specificity of GSK461364 for Plk1 is more than 1000-fold over Plk2/3.
|
| T2634 |
Ro3280
|
1062243-51-9
|
98%
|
|
|
Ro3280 (Ro5203280) is an effective, specific inhibitor of PLK1(IC50=3, Kd=0.09 nM).
|
| T2704 |
MLN0905
|
1228960-69-7
|
97.17%
|
|
|
MLN0905 (PLK1 Inhibitor) is an effective PLK1 inhibitor(IC50=2 nM).
|
| T16750 |
Rigosertib
|
592542-59-1
|
97.33%
|
|
|
Rigosertib (ON-01910) is a selective and non-ATP-competitive inhibitor of PLK1 (IC50: 9 nM). Rigosertib is a multi-kinase inhibitor and a selective anti-cancer a...
|
| T7384 |
Ocifisertib（CFI-400945 free base）
|
1338806-73-7
|
97.56%
|
|
|
CFI-400945 is an potent, selective and orally active inhibitor of polo-like kinase 4(PLK4; Ki value of 0.26 nM).
|
| T10215 |
AAPK-25
|
2247919-28-2
|
97.79%
|
|
|
AAPK-25 is a potent and selective Aurora/PLK dual inhibitor with anti-tumor activity, which can cause mitotic delay and arrest cells in prometaphase, followed by...
|
| T7200 |
TAK-960
|
1137868-52-0
|
98%
|
|
|
TAK-960 is an orally bioavailable, selective inhibitor of Plks with IC50 values of 0.8, 16.9, and 50.2 nM for Plk1, Plk2, and Plk3, respectively.
|
| T6019 |
Volasertib
|
755038-65-4
|
98.04%
|
|
|
Volasertib (BI 6727) (BI-6727) is a potent inhibitor of PLK1 (IC50: 0.87 nM), inducing mitotic arrest and apoptosis. It also inhibits PLK2/PLK3 (IC50s: 5/56 nM)....
|
| T1839 |
Mps1-IN-2
|
1228817-38-6
|
98.07%
|
|
|
Mps1-IN-2 is a potent, selective and ATP-competitive dual Mps1/Plk1 inhibitor.
|
| T6247 |
Onvansertib
|
1034616-18-6
|
98.08%
|
|
|
Onvansertib (NMS-1286937), an oral, specific Polo-like Kinase 1 (PLK1) inhibitor, is with IC50 of 2 nM. The specificity of NMS-P937 forPLK1 is 5000-fold higher o...
|
| T6173 |
BI 2536
|
755038-02-9
|
98.31%
|
|
|
BI2536 is an effective Plk1 inhibitor (IC50: 0.83 nM). It has 4- and 11-fold greater selectivity than Plk2 and Plk3.
|
| T22288 |
(1E)-CFI-400437 dihydrochloride
|
1247000-76-5
|
98.36%
|
|
|
(1E)-CFI-400437 dihydrochloride (CFI-400437 dihydrochloride) is a selective and potent polo-like kinase 4 (PLK4) inhibitor.
|
| T19664 |
ON1231320
|
1312471-39-8
|
98.69%
|
|
|
ON1231320 (GBO-006) is a Polo-like kinase 2 (PLK2) inhibitor.
|
| T14927 |
Centrinone
|
1798871-30-3
|
98.76%
|
|
|
Centrinone (LCR-263) (LCR-263) is a reversible inhibitor of polo-like kinase 4 (PLK4; Ki:0.16 nM).
|
| T3643 |
HMN-176
|
173529-10-7
|
98.99%
|
|
|
HMN-176 is a stilbene derivative which inhibits mitosis, interfering with polo-like kinase-1 (plk1).
|
| T2271 |
SBE13 Hydrochloride
|
1052532-15-6
|
99.01%
|
|
|
SBE13 Hydrochloride (SBE 13 HCl) is an effective and specific PLK1 inhibitor (IC50: 0.2 nM); no inhibition om Aurora A kinase, Plk2/3.
|
| T6338 |
PHA-680632
|
398493-79-3
|
99.03%
|
|
|
PHA-680632 is potent inhibitor of Aurora A, Aurora B and Aurora C with IC50 of 27 nM, 135 nM and 120 nM, respectively. It has 10- to 200-fold higher IC50 for FGF...
|
| T5818 |
Rigosertib sodium
|
592542-60-4
|
99.07%
|
|
|
Rigosertib sodium (ON-01910), a non-ATP-competitive inhibitor of PLK1(IC50=9 nM), exhibits 30-fold higher specificity activity over Plk2 and no effect on Plk3.
|
| T0973 |
Pyridoxine
|
65-23-6
|
99.18%
|
|
|
Pyridoxine (Vitamin B6) is the 4-methanol form of vitamin B6 and is converted to pyridoxal 5-phosphate in the body. Although pyridoxine and vitamin B6 are still ...
|
